

18 May 2023

Diaceutics PLC
("Diaceutics" or "the Company")

Results of Annual General Meeting

Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharmaceutical industry, is pleased to announce that all resolutions proposed at its Annual General Meeting held earlier today, were duly passed.

The proxy votes received from shareholders in respect of each resolution are set out below and are available on the Company's website www.diaceutics.com

Resolution	For (excluding at Chair's discretion)		Against		Total votes cast	Withheld
	Number of votes	%*	Number of votes	%*		
1 Ordinary resolution to receive and consider the 2022 Financial Statements	60,055,552	100.00%	0	0.00%	60,055,552	Nil
2 Ordinary resolution to approve the directors' remuneration report	51,885,466	89.43%	6,131,086	10.57%	60,055,552	2,039,000
3 Ordinary resolution to re-elect Peter Keeling as a director	59,406,925	98.92%	648,627	1.08%	60,055,552	Nil
4 Ordinary resolution to re-elect Michael Wort as a director	55,788,593	92.89%	4,266,959	7.11%	60,055,552	Nil
5 Ordinary resolution to re-appoint Ernst & Young as auditors	60,055,552	100.00%	0	0.00%	60,055,552	Nil
6 Ordinary resolution to authorise the directors to determine the remuneration of the auditors	60,055,552	100.00%	0	0.00%	60,055,552	Nil
7 Ordinary resolution to authorise the directors to allot shares	60,055,552	100.00%	0	0.00%	60,055,552	Nil
8 Special resolution to authorise the directors to disapply pre-emption rights	60,055,202	99.9%	350	0.01%	60,055,552	Nil
9 Special resolution to authorise the directors to purchase own shares	59,976,122	100.00%	0	0.00%	60,055,552	79,430

*Percentage of votes cast excludes withheld votes

Enquiries:

Diaceutics PLC

Peter Keeling, Chief Executive Officer
Nick Roberts, Chief Financial Officer

Via Alma PR

Stifel Nicolaus Europe Limited (Nomad & Broker)

Ben Maddison, Nick Harland, Nick Adams

Tel: +44 (0)20 7710 7600

Alma PR

Caroline Forde, Kieran Breheny, Matthew Young, Kinvara Verdon

Tel: +44(0)20 3405 0205

diaceutics@almapr.co.uk

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharmaceutical and life science companies with solutions and technology for the commercialisation of their precision medicines, enabled by the proprietary DXRX platform.

DXRX is the world's first diagnostic commercialisation platform for precision medicine, utilising a global network of affiliate laboratories to deliver multiple pipelines of real-world healthcare data insights, advisory services and innovative platform enabled solutions.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

RAGGPURWAUPWGUR